Format

Send to

Choose Destination
AIDS. 2012 Jan 2;26(1):1-9. doi: 10.1097/QAD.0b013e32834d606e.

Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).

Author information

1
University of Hawai'i at Manoa, Honolulu, Hawaii, USA.

Abstract

OBJECTIVE:

We investigated the impact of neutralizing antibodies (NAbs) on CD4 T-cell count and viral load in a cohort of HAART recipients who underwent extended structured treatment interruption.

DESIGN:

Substudy of NAb in the AIDS Clinical Trials Group 5170 trial.

METHODS:

Early plasma samples from 50 volunteers who discontinued HAART were evaluated in a peripheral blood mononuclear cell-based neutralization assay against a panel of four subtype B primary isolates.

RESULTS:

We found that high-titer (90% inhibitory dose > 500) NAb against two or more isolates was associated with reduced viral load (P = 0.003 at 12-week posttreatment interruption). This effect faded with time, losing significance (P = 0.161) by study conclusion. Participants possessing the highest NAb levels against individual isolates appeared more likely to have lower viral loads with the association gaining significance against the R5-tropic primary isolate US1 (P = 0.005). There was no association between broader neutralization and CD4 T-cell slope over time.

CONCLUSION:

The data suggest that high-titer NAb responses at the time of treatment interruption are associated with reduced viral load over time, but not CD4(+) T-cell decline.

PMID:
21971356
DOI:
10.1097/QAD.0b013e32834d606e
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center